Patients just beginning treatment with different EGFR inhibiting drugs, such as Vectibix or Erbitux, were randomly told to apply sunscreen or a placebo cream twice a day for four weeks. The study was doubled-blinded — neither the patients nor their doctors knew who was getting the real sunscreen.
Doctors monitored the development of skin rash and patients reported on how rash affected their quality of life during the four weeks of sunscreen or placebo and for an additional four weeks after the study ended.
During the time sunscreen was being used and for the following month, there was no difference in occurrence or severity of rash nor in patient-reported quality of life. Read the rest of this entry »